Randy F. Sweis
Cited by
Cited by
WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
JJ Luke, R Bao, RF Sweis, S Spranger, TF Gajewski
Clinical Cancer Research 25 (10), 3074-3083, 2019
T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection
JA Trujillo, RF Sweis, R Bao, JJ Luke
Cancer immunology research 6 (9), 990-1000, 2018
Molecular drivers of the non–T-cell-inflamed tumor microenvironment in urothelial bladder cancer
RF Sweis, S Spranger, R Bao, GP Paner, WM Stadler, G Steinberg, ...
Cancer immunology research 4 (7), 563-568, 2016
Silver-catalyzed [2+ 2] cycloadditions of siloxy alkynes
RF Sweis, MP Schramm, SA Kozmin
Journal of the American Chemical Society 126 (24), 7442-7443, 2004
Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas
F Meric-Bernstam, RF Sweis, FS Hodi, WA Messersmith, RHI Andtbacka, ...
Clinical Cancer Research 28 (4), 677-688, 2022
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
CH Lee, AY Shah, D Rasco, A Rao, MH Taylor, C Di Simone, JJ Hsieh, ...
The lancet oncology 22 (7), 946-958, 2021
Germline genetic contribution to the immune landscape of cancer
RW Sayaman, M Saad, V Thorsson, D Hu, W Hendrickx, J Roelands, ...
Immunity 54 (2), 367-386. e8, 2021
Brønsted acid-promoted cyclizations of 1-siloxy-1, 5-diynes
J Sun, SA Kozmin
Journal of the American Chemical Society 127 (39), 13512-13513, 2005
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
D Bedognetti, M Ceccarelli, L Galluzzi, R Lu, K Palucka, J Samayoa, ...
Journal for immunotherapy of cancer 7, 1-23, 2019
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy
C Labbate, K Hatogai, R Werntz, WM Stadler, GD Steinberg, S Eggener, ...
Journal for immunotherapy of cancer 7, 1-6, 2019
Do clinicians know which of their patients have central venous catheters? A multicenter observational study
V Chopra, S Govindan, L Kuhn, D Ratz, RF Sweis, N Melin, R Thompson, ...
Annals of internal medicine 161 (8), 562-567, 2014
FGFR3 alterations in the era of immunotherapy for urothelial bladder cancer
A Kacew, RF Sweis
Frontiers in Immunology 11, 575258, 2020
Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study
F Meric-Bernstam, RF Sweis, S Kasper, O Hamid, S Bhatia, R Dummer, ...
Clinical Cancer Research 29 (1), 110-121, 2023
Wnt–β-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression
J Quandt, S Arnovitz, L Haghi, J Woehlk, A Mohsin, M Okoreeh, ...
Nature immunology 22 (4), 471-484, 2021
Tumor endothelial inflammation predicts clinical outcome in diverse human cancers
SP Pitroda, T Zhou, RF Sweis, M Filippo, E Labay, MA Beckett, ...
Public Library of Science 7 (10), e46104, 2012
Hallmarks of resistance to immune-checkpoint inhibitors
M Karasarides, AP Cogdill, PB Robbins, M Bowden, EM Burton, ...
Cancer immunology research 10 (4), 372-383, 2022
Mechanistic and pharmacologic insights on immune checkpoint inhibitors
RF Sweis, JJ Luke
Pharmacological research 120, 1-9, 2017
Analysis of impact of post-treatment biopsies in phase I clinical trials
RF Sweis, MW Drazer, MJ Ratain
Journal of Clinical Oncology 34 (4), 369, 2016
Concurrent EGFR mutation and ALK translocation in non-small cell lung cancer
RF Sweis, S Thomas, B Bank, P Fishkin, C Mooney, R Salgia
Cureus 8 (2), 2016
Correlation of WNT/β-catenin pathway activation with immune exclusion across most human cancers.
JJ Luke, R Bao, S Spranger, RF Sweis, T Gajewski
Journal of Clinical Oncology 34 (15_suppl), 3004-3004, 2016
The system can't perform the operation now. Try again later.
Articles 1–20